The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 29, 2023
Filed:
Mar. 26, 2019
Applicant:
Id4pharma, Llc, Pittsburgh, PA (US);
Inventors:
Xiang-Qun Xie, Sewickley, PA (US);
Garson David Roodman, Indianapolis, IN (US);
Kyaw-Zeyar Myint, Ashland, MA (US);
Noriyoshi Kurihara, Pittsburgh, PA (US);
Assignee:
ID4PHARMA, LLC, Pittsburgh, PA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 229/36 (2006.01); C07D 309/40 (2006.01); C07C 211/50 (2006.01); C07C 317/34 (2006.01); C07C 217/58 (2006.01); C07C 217/76 (2006.01); C07C 219/06 (2006.01); C07D 241/44 (2006.01); C07C 229/14 (2006.01); C07D 487/04 (2006.01); C07C 235/48 (2006.01); C07C 251/76 (2006.01); A61K 31/137 (2006.01); A61K 31/351 (2006.01); A61K 31/495 (2006.01); A61K 31/519 (2006.01); A61K 31/15 (2006.01); A61K 31/498 (2006.01); A61K 45/06 (2006.01); C07C 249/16 (2006.01); C07D 309/32 (2006.01); C07D 475/08 (2006.01); C12N 5/09 (2010.01); A61K 31/216 (2006.01);
U.S. Cl.
CPC ...
C07C 229/36 (2013.01); A61K 31/137 (2013.01); A61K 31/15 (2013.01); A61K 31/216 (2013.01); A61K 31/351 (2013.01); A61K 31/495 (2013.01); A61K 31/498 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); C07C 211/50 (2013.01); C07C 217/58 (2013.01); C07C 217/76 (2013.01); C07C 219/06 (2013.01); C07C 229/14 (2013.01); C07C 235/48 (2013.01); C07C 249/16 (2013.01); C07C 251/76 (2013.01); C07C 317/34 (2013.01); C07D 241/44 (2013.01); C07D 309/32 (2013.01); C07D 309/40 (2013.01); C07D 475/08 (2013.01); C07D 487/04 (2013.01); C12N 5/0693 (2013.01);
Abstract
A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.